Studies have shown that CRC cells with downregulated levels of PTPRS show a higher response to MEK/ERK inhibition due to a lack of adaptive resistance response that allows a bypass of MEK/ERK drug blockade, unlike the parental cells. The gene discussed is PTPRS; the disease is colorectal carcinoma.